Search

… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology … Biology/Molecular Biology. What is Klein’s connection to RNA therapeutics? “At the end of the 80s, I wrote my master’s …

… Always excited about RNA therapies He is one of the founders of ProQR, but even … as they say. Gerard Platenburg What made you pursue RNA therapy as a potential treatment for these diseases?  “Well, …

… Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed …

… Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology. This month several ProQRians … here: Axiomer technology - RNA base editing What is RNA therapy? TIDES Europe 2022 Conference …

… am extremely passionate about ProQR’s focus on developing RNA technologies that allow us to develop potentially … unmet need.” How do you distinguish ProQR from other RNA therapy companies? “ProQR is pioneering a next-generation RNA … the laboratories where our scientists develop our novel RNA therapies, putting science, literally, at the heart of …

… study which aimed to explore whether the investigational RNA therapy sepofarsen was effective and safe for individuals … more from the ongoing analyses and as they work to advance RNA therapies to potentially help children, adults, and …

… “We have started testing sepofarsen, our investigational RNA therapy for Leber congenital amaurosis, in the organoids as …